摘要
目的探讨放疗联合内分泌及双膦酸盐同期治疗晚期前列腺癌骨转移患者的近期临床疗效。方法收集漯河市中心医院肿瘤科120例合并骨转移的晚期前列腺癌病人的临床资料,将接受放疗联合同期内分泌及双膦酸盐治疗的60例病人作为观察组,将仅接受内分泌联合双膦酸盐治疗的60例病人作为对照组,治疗12个月。记录两组肿瘤标志物水平、疼痛缓解程度、骨质破坏变化、不良骨事件、不良反应发生情况,对比分析两组近期治疗的临床效果。结果观察组血清肿瘤标志物水平下降率(86. 7%)高于对照组(65. 0%);疼痛缓解率(95%)高于对照组(80%);骨质破坏修复率(88. 3%)高于对照组(75%);不良骨事件发生率(25%)低于对照组(38. 3%),对比差异具有统计学意义(P <0. 05)。不良反应发生情况,观察组骨髓抑制发生率明显高于对照组,且观察组有重度骨髓抑制发生,差异具有统计学意义(P <0. 05)。结论放疗联合内分泌及双膦酸盐同期治疗前列腺癌骨转移效果确切,不良反应可耐受,值得临床推广应用。
Objective To investigate the short-term clinical efficacy of radiotherapy combined with endocrine and bisphosphonate in the treatment of advanced prostate cancer with bone metastases.Methods The clinical data of 120 patients with advanced prostate cancer with bone metastases from the Department of Oncology of Luohe Central Hospital were collected.Sixty patients who received radiotherapy combined with concurrent endocrine and bisphosphonate treatments were included in the observation group and only received endocrine combined with bisphosphine.Sixty patients treated with acid salt were treated as a control group for 12 months.The tumor marker levels,pain relief,bone destruction changes,adverse bone events,and adverse reactions were recorded in the two groups.The clinical effects of the two groups were compared.Results The decline rate of serum tumor markers in the observation group(86.7%)was higher than that in the control group(65.0%);The pain relief rate(95%)was higher than that in the control group(80%);The bone destruction repair rate(88.3%)was higher than that in the control group(75%).The incidence of adverse bone events(25%)was lower than that of the control group(38.3%)(P<0.05).The incidence of adverse reactions,the incidence of myelosuppression in the observation group was significantly higher than that of the control group,and the observation group had severe myelosuppression,which was statistically different.Conclusion Radiotherapy combined with endocrine and bisphosphonate for the treatment of bone metastasis of prostate cancer is effective,and adverse reactions can be tolerated,which is worthy of clinical application.
作者
张国耀
史磊
李玉伟
ZHANG Guo-yao;SHI lei;Li Yu-wei(Department of Oncology,Luohe Central Hospital,Luohe,Henan 462000,China)
出处
《医药论坛杂志》
2018年第12期17-19,22,共4页
Journal of Medical Forum
基金
2015年河南省医学科技攻关计划指导性项目(201504093)
关键词
放疗
内分泌
前列腺癌
骨转移
双膦酸盐
Radiotherapy
Endocrine
Prostate cancer
Bone metastasis
Bisphosphonate
